ArticleMikrochimica acta2026
A smartphone-integrated aptasensor for SARS-CoV-2 S1 protein using multi-walled carbon nanotube-ionic liquid modified electrodes.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aptamer-gold nanoparticle-based lab-in-a-tube colorimetric detection of malathion: evaluation with classical and digital readout techniques.Turkish journal of chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An aptamer-based electrochemical biosensor was developed for the highly sensitive detection of SARS-CoV-2 S1 protein using electrodes modified with a multi-walled carbon nanotube–ionic liquid (MWCNT–IL) composite. Comprehensive electrochemical and microscopic characterizations of the MWCNT–IL material were conducted, followed by the optimization of experimental parameters including ionic liquid concentration and surface modification time. Critical parameters for aptasensor construction, aptamer concentration, immobilization time, and aptamer-protein interaction time, were also optimized. Under optimal conditions, the biosensor exhibited a wide linear response from 1 fg/mL to 1 ng/mL in buffer, with a remarkably low limit of detection (LOD) of 0.11 fg/mL. Selectivity evaluations against hemagglutinin antigen (HA) and MERS-CoV-S1 (MERS) protein confirmed the sensor’s high specificity for SARS-CoV-2 S1 protein. The sensor’s applicability in artificial saliva was also successfully demonstrated, yielding accurate quantification and low detection limits (LOD: 0.16 fg/mL). Recovery studies in artificial saliva demonstrated satisfactory accuracy, with recoveries ranging from 108% to 120% and high reproducibility. Notably, the aptasensor maintained strong selectivity even in the presence of matrix interferents. Furthermore, the potential for point-of-care use was assessed via a smartphone-connected portable potentiostat. This handheld system enabled a linear detection range of 1 fg/mL to 1 ng/mL with a LOD of 0.83 fg/mL. Collectively, these results highlight the MWCNT–IL-based aptasensor as a robust, low-cost, and portable platform for rapid COVID-19 diagnostics, offering considerable promise for deployment in point-of-care and resource-constrained environments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.